Rankings
▼
Calendar
RIGL Q4 2022 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
RIGL
Rigel Pharmaceuticals, Inc.
$541M
Q4 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$51M
+151.3% YoY
Gross Profit
$51M
99.3% margin
Operating Income
$2M
4.1% margin
Net Income
$1M
2.7% margin
EPS (Diluted)
$0.10
QoQ Revenue Growth
+128.8%
Cash Flow
Operating Cash Flow
-$22M
Free Cash Flow
-$22M
Stock-Based Comp.
$4M
Balance Sheet
Total Assets
$134M
Total Liabilities
$148M
Stockholders' Equity
-$14M
Cash & Equivalents
$24M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$51M
$20M
+151.3%
Gross Profit
$51M
$20M
+155.7%
Operating Income
$2M
-$21M
+109.7%
Net Income
$1M
-$23M
+106.2%
Revenue Segments
Gross product sales
$33M
32%
Contract revenues from collaborations
$26M
26%
Product sales, net
$23M
23%
Development milestones
$20M
20%
License revenues
$5M
5%
Government contract
$2M
2%
Research and development services and others
$1M
1%
Discounts and allowances
-$10M
-10%
← FY 2022
All Quarters
Q1 2023 →